A BILL to amend and reenact §§ 38.2-3465, 38.2-3467, and 38.2-3469 of the Code of Virginia and to amend the Code of Virginia by adding a section numbered 38.2-3467.1, relating to health insurance; pharmacy benefits management; requirements and prohibited conduct; retail pharmacy network access standards; enforcement; civil penalty.
HB1271 would significantly expand Virginia’s regulation of pharmacy benefits managers (PBMs) and the carriers that contract with them. The bill revises statutory definitions related to pharmacy benefits management, rebates, spread pricing, retail pharmacy networks, and 340B contract pharmacies, and it adds a new section setting out additional PBM contract restrictions and disclosure obligations. It also broadens prohibited conduct by barring practices such as misleading advertising, discriminatory reimbursement, retaliation against pharmacies, network participation fees, spread pricing, and certain restrictions on pharmacy choice or 340B participation.
The bill further requires PBMs to maintain an electronic claim inquiry system, disclose rebate and audit recoupment information to clients, provide certain contract and utilization data to regulators and plan sponsors on request, preserve network development records, and file quarterly reports. It also limits how PBMs may reference specific pharmacies or hospitals in materials unless they list all participating providers in the relevant networks. Enforcement authority is strengthened by giving the Attorney General civil investigative demand power, authority to seek injunctions, and the ability to recover civil penalties of up to $5,000 per willful violation, while the State Corporation Commission remains the primary enforcing agency for the article.
The bill’s impact on state law would be to impose more detailed conduct standards on PBMs and carriers operating in Virginia, especially around reimbursement practices, network access, transparency, and 340B-related treatment. It would affect insurers, self-funded employer plans to the extent covered by the bill, PBMs, retail pharmacies, mail-order pharmacies, contract pharmacies, covered entities, and consumers using prescription drug coverage. It also appears intended to curb PBM-affiliate advantages and increase oversight of prescription drug pricing and network practices.
The available legislative history suggests little support at the committee stage. The only recorded vote shows a 9-0 subcommittee recommendation to strike the bill from the docket, and the bill was left in Labor and Commerce. With no recorded transcript discussion provided, the sentiment can be inferred as generally unfavorable or at least not ready for advancement, likely reflecting concerns about the breadth of the regulation, compliance burdens, or the policy implications for PBMs and carriers.
The main points of contention are likely the bill’s restrictions on PBM business practices, especially spread pricing, affiliate network treatment, reimbursement rules, and disclosure requirements. PBMs and carriers may object to the operational and competitive constraints, while pharmacies, 340B entities, and consumer advocates would likely favor the bill’s transparency and anti-discrimination provisions. The inclusion of Attorney General enforcement and civil penalties also suggests a stronger regulatory posture that may have contributed to opposition or hesitation in committee.
HB1271 would amend §§ 38.2-3465, 38.2-3467, and 38.2-3469 of the Code of Virginia and add § 38.2-3467.1, creating a more detailed regulatory framework for pharmacy benefits management. It would prohibit spread pricing, certain fees and reimbursement practices, discriminatory treatment of 340B contract pharmacies, and restrictions on pharmacy choice, while requiring PBMs to disclose rebate and pricing information, maintain records, and provide data to regulators and plan sponsors. The bill also expands enforcement by the State Corporation Commission and the Attorney General, including civil investigative demands, injunctions, and civil penalties.
The recorded committee action indicates negative or at least non-advancing sentiment: a subcommittee voted 9-0 to recommend striking the bill from the docket, and the measure was left in Labor and Commerce. With no transcript available, the overall tone appears to have been skeptical of the bill’s scope or regulatory burden rather than supportive.
The likely areas of contention are the bill’s broad limits on PBM contracting and pricing practices, including the ban on spread pricing, restrictions on affiliate favoritism, and requirements to disclose rebates, contracts, and utilization data. PBMs and carriers would be the most likely opponents because the bill directly constrains their business model and increases oversight, while retail pharmacies, 340B covered entities, and some consumer advocates would likely support the bill’s transparency, access, and anti-retaliation provisions. The Attorney General enforcement provisions and civil penalties may also be a point of concern for regulated entities.